Trial shows nearly one-third reduction in invasive disease progression or distant recurrence at follow-up
TUESDAY, Dec. 16, 2025 (HealthDay News) – Giredestrant, a selective estrogen receptor antagonist and degrader given as an adjuvant therapy, shows significant improvement in invasive disease-free survival (iDFS) in patients with early-stage, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 9 to 12 in San Antonio.
Aditya Bardia, M.D., M.P.H., from the University of California Los Angeles, and colleagues conducted a global, randomized, open-label trial in which 4,170 patients with HR-positive, HER2-negative early breast cancer (stages I to III) were assigned (1:1) to receive either 30 mg of oral giredestrant daily or one of four standard-of-care endocrine therapies (tamoxifen, letrozole, anastrozole, or exemestane). All patients received surgery and, if indicated, completed adjuvant or neoadjuvant chemotherapy.
The researchers report that after a median follow-up of 32.3 months, patients who received giredestrant had significantly better iDFS than those receiving standard-of-care endocrine therapy and were 30 percent less likely to develop invasive disease progression at follow-up. Additionally, patients who received giredestrant were 31 percent less likely than those in the standard-of-care arm to experience distant recurrence at follow-up. Overall survival data were immature but showed a positive trend in favor of giredestrant.
“Giredestrant demonstrated clinically meaningful superiority to currently well-established standard-of-care endocrine agents: aromatase inhibitors and tamoxifen,” Bardia said in a statement. “What is particularly striking and relevant is early separation of [the overall survival] curves.”
Several authors disclosed financial ties to pharmaceutical companies, including F. Hoffmann-La Roche, which manufactures giredestrant and funded the study.
Implant, Patient Survival Do Not Differ for Robotic and Conventional Total Joint Replacement 
Gap Found Between Awareness of Breast Cancer Risk and Risk-Reducing Behavior 
Exercise Intervention Linked to Improved Attention, Memory in Breast Cancer 
Physical Therapist-Supervised Exercise Improves Outcomes After ACL Reconstruction 
Ultrasound-Guided Hydrodissection Yields Improvements in Carpal Tunnel 
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing 
2016 to 2024 Saw Increase in Patients Using Medical Cannabis 
Early Complications Common in Older Kidney Transplant Recipients 
.jpg)
